Mapping drug-drug interactions in pharmacokinetic boosting of olaparib
- 19 January 2026
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 96 (1) , 9
Abstract
Introduction In pharmacokinetic (PK) boosting, an intentional drug-drug interaction (DDI) is used to increase the exposure of another drug. PK boosting of the anticancer drug olaparib with the potent Cytochrome P450 (CYP3A)-inhibitor cobicistat can improve oral bioavailability, tolerability, and affordability. Cancer patients often present with many comedications that can also be affected by CYP3A-inhibitors, which requires thorough assessment of DDIs. This may hamper the feasibility of boosting. Here, we report potential DDIs between cobicistat and comedication in a retrospective cohort of patients treated with olaparib and how these DDIs can be mitigated. Methods Patients who received olaparib between April 2017 and February 2024 were included. Comedications at the start of olaparib treatment were screened for potential DDIs with cobicistat if PK boosting would have been initiated in these patients. Relevant DDIs were reviewed by an expert panel of pharmacists and clinical pharmacologists and recommendations for mitigating interventions were formulated. Results In total, 97 patients were included with a median of six concomitant medications per patient (range 0–13). 59% of patients presented with at least one relevant DDI. With the recommended interventions, 14% of patients had a DDI that required additional monitoring and 1% had a contra-indicated DDI. Conclusions DDIs were highly prevalent when PK boosting of olaparib is applied. Nonetheless, nearly all DDIs could be mitigated by an intervention and most interventions could be applied without additional monitoring. PK boosting of olaparib with cobicistat is thus considered feasible with appropriate expertise and resources.Keywords
Funding Information
- ZonMw (10140021910005)
This publication has 11 references indexed in Scilit:
- Pharmacokinetic boosting of olaparib: A randomised, cross-over study (PROACTIVE-study)European Journal of Cancer, 2023
- Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in OncologyClinical Pharmacokinetics, 2022
- Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsClinical Pharmacology & Therapeutics, 2022
- Boosting the oral bioavailability of anticancer drugs through intentional drug–drug interactionsBasic & Clinical Pharmacology & Toxicology, 2021
- An Arm and a Leg: The Rising Cost of Cancer Drugs and Impact on AccessAmerican Society of Clinical Oncology Educational Book, 2021
- Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug InteractionClinical and Translational Science, 2019
- Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanesCancer Chemotherapy and Pharmacology, 2019
- Cobicistat versus ritonavir boosting and differences in the drug–drug interaction profiles with co-medicationsJournal of Antimicrobial Chemotherapy, 2016
- Statin Toxicity From Macrolide Antibiotic CoprescriptionAnnals of Internal Medicine, 2013
- Prevalence of comedications and effect of potential drug–drug interactions in the Swiss HIV Cohort StudyAntiviral Therapy, 2009